Clinical Trials Browser

INDUSTRY × Recurrence × ofatumumab × Clear all

NCT01578707 2019-12-18

RESONATE™

Phase 3 Completed

391 enrolled 14 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2 Completed

49 enrolled 13 charts

Lymphoma, Non-Hodgkin, Recurrence

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2 Completed

99 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01014208 2015-08-07

ORCHARRD

Phase 3 Completed

447 enrolled 21 charts

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Completed

61 enrolled 25 charts

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse